SuperQ enters commercial deal with Science & Humans

Executive Summary

• SuperQ Quantum Computing Inc. has entered into a commercial agreement with Science & Humans (S&H), a Canadian hormonal health company, to deploy quantum-artificial-intelligence-powered clinician solutions.
• SuperQ will architect and deliver AI clinicians enhanced by quantum-computing-based optimization for integration into S&H’s real-world health care workflows, aiming to address increased clinical demands and user growth.
• The collaboration leverages SuperQ’s "Super" platform, which enables interoperability across quantum hardware types and integrates high-performance classical compute, positioning the project as a bridge between quantum AI architecture and commercial health care solutions.

Key Details

• Parties Involved: SuperQ Quantum Computing Inc. (provider) and Science & Humans (S&H) (client/partner).
• Nature of Agreement: Commercial agreement for the deployment of quantum-AI clinician systems.
• Scope of Work: SuperQ will architect and deliver AI clinicians enhanced by quantum-computing-based optimization. S&H provides domain expertise and knowledge base from its scientific and clinical teams.
• Technology Stack: Utilizes SuperQ’s "Super" platform, which implements interoperability across quantum hardware types (annealing, gate-based, and hybrid classical/quantum) and integrates high-performance classical compute and AI-driven orchestration.
• Strategic Context: The agreement follows Nvidia’s unveiling of the NVQLink interconnect at Nvidia GTC DC, highlighting a shift toward hybrid classical-quantum infrastructure. SuperQ’s platform is designed to orchestrate classical compute, AI pipelines, and multiple quantum hardware types.
• Project Roadmap (Phased Deployment):
  1. Triaging patients and enhancing diagnostic decision support.
  2. Streamlining prescription workflows.
  3. Extending into chronic disease management, real-time patient monitoring, and broader health care system logistics.
• Target Domains: Patient triage, autonomous monitoring, treatment optimization, and decision support in sensitive care environments.
• Partner Profile: S&H is an Ontario-based provider of hormonal health care (menopause, thyroid conditions, sexual health). It was ranked No. 32 on Deloitte Canada's 2025 Technology Fast 50 list, reflecting 970% growth over the prior three years.
• Current Status: The parties have reached the Minimum Viable Product (MVP) stage and aim to reach full production in the coming months.

Notable Quotes

• Aftab Pashaw, CEO of S&H: "We are excited to be the first to explore frontier AI and quantum technologies in clinical diagnosis and treatment. SuperQ is playing a key role in the development, integration and enhancement of our clinical AI systems. Together, we have already reached the MVP stage and aim to reach full production in the coming months."
• Dr. Muhammad Khan, CEO and Board Chair of SuperQ: "Commercial use cases for the Super platform and related professional services are growing by the day. The Science & Humans project signals that quantum AI is now ready to transform clinician workflows, where the margin for error is minimal and the stakes are highest."